Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. This press release contains ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced it ...